We are a strategic drug development partner for the biopharma industry. We combine uniquely structured investment deals, cutting-edge cost reduction strategies and a smart outsourcing platform to help our partners advance their programs towards key clinical and financial milestones.
We ourselves are not a CRO. However, we provide a very broad range of CRO services through our General Contractor Platform whereby our clients gain access to a global network of CROs and their services via a single relationship with InSymbiosis.
Thanks to InSymbiosis’ unique financial model our clients only pay for the pass through costs of the CROs and not for our value added services. InSymbiosis is able to offer this unique financial proposition since we specialize in leveraging a variety of financial incentives that fund our operations.
InSymbiosis acts as a general contractor whereby our clients outsource to CROs via contracts with InSymbiosis. Combining this with our expertise in accessing a variety of financial incentives, InSymbiosis can provide direct discounts to the prices offered by the CROs.
From a financial perspective, our clients benefit from lower outsourcing costs and potentially, investments. Further, our clients benefit from a variety of value added services which include but are not limited to:
In all cases, our services and involvement in our client’s programs are customized to their exact needs.
InSymbiosis places a large emphasis on confidentiality. We maintain mutual confidentiality agreements with all of our clients, CROs and external consultants. In addition, InSymbiosis has taken a stance not to provide press releases or news feeds on the deals we do with our clients (with the exception of investment deals), thereby keeping the very existence of the relationships confidential. However, upon request, we can provide a list of references from clients who have expressly given permission to provide their details to potential future clients and partners.
InSymbiosis works with a range of biopharma companies (virtual, small, and midsize) from around the world as well as large global pharma companies. The majority of our work is with human therapeutics companies and occasionally companies developing veterinary products.
As of 2019, InSymbiosis has worked on programs supporting over 120 therapeutic products covering small molecules, biologic drugs and more recently, cell-based therapies.
InSymbiosis specializes in the oversight of drug development programs and CRO management. Within this broad area we spend a lot of our time involved in candidate selection programs, non-clinical toxicology programs (supporting IND’s and NDA’s), formulation and CMC programs leading to GMP drug substance and drug product and clinical phase programs (Phases I, II and III).
We are indication agnostic and since our inception in 2005, we have worked on most of the main indications of interest to the pharma industry.
Typically we make equity-based investments but in some cases we will consider asset-centric investments. Typically we invest during the preclinical to early clinical stages and from Seed to Series A rounds
We normally invest in companies with a therapeutic pipeline (small molecule or biologics) that as a minimum have achieved an animal proof of concept and are 6-12 months away (or less) from starting formal IND enabling studies through to companies in early clinical stages. We are therapeutically agnostic and opportunistic
This varies depending on the project and situation but can range from tens of thousands to high hundreds of thousands.
Our Experts Network (http://www.insymbiosis.com/experts-network/) is a portfolio of industry proven drug development experts from different disciplines (CMC, toxicology, etc.). It comprises both internal and external experts who provide consulting services to our clients.
By talking to InSymbiosis and explaining your needs, we are able to help you navigate to the right expert within our network, or if required, reach beyond our network to find the right expertise.
Upon selecting the consultant you wish to engage, InSymbiosis will send you a consulting agreement. Once the consulting agreement is in place, consulting rates can be obtained for hourly, daily and project based engagements.
We are actively growing our Experts Network and welcome you to contact us. Please email us your biography and resume to email@example.com
The benefits are multi-faceted, including but not limited to:
Outsource drug development activities to a network of world-class audited CROs, CMOs and laboratories
Benefit from a unique financial structure that provides directly discounted CRO rates
Investment in assets staged from late discovery to Phase II clinical
Uniquely structured investment deals including both cash for equity and project/asset specific investments
Rapid due diligence process
Access to a network of drug development experts and specialists
Flexibility to hire an expert for 1 hour, 1 day or for an entire program
Experts Network can be combined with CRO Optimizer or investment deals
InSymbiosis is a strategic drug development partner for the biopharma industry. By combining uniquely structured investment deals, cutting-edge cost reduction strategies and a smart outsourcing platform, we help our partners advance their programs towards key clinical and financial milestones. As a result, InSymbiosis has become the drug development partner of choice for many biopharma companies.About us